Ranked among the top 5% in the industry, Healthy Yuan's S&P Global ESG rating has once again achieved a high score and been included in the list.
Published Time:
2025-01-21
Recently, the results of the S&P Global Sustainability Assessment were released. HealthGen (600380.SH) stood out with its excellent Environmental, Social, and Governance (ESG) performance. In the 2024 S&P Global Corporate Sustainability Assessment, it received a score of 69, surpassing 95% of its peer companies and ranking third among participating pharmaceutical companies in China.

S&P Global is one of the most authoritative and largest mainstream ESG rating agencies internationally. Its annually published sustainability assessment results are an important basis for mainstream investment decisions in the international capital market and a significant annual achievement reflecting a company's sustainable development practices.

Outstanding Achievements: Repeatedly Recognized by Authoritative ESG Rating Agencies
In recent years, with the deepening of the concept of sustainable development, ESG management capabilities have been regarded as a key indicator for evaluating listed companies, and various listed companies have been creating new ESG 'business cards'. Thanks to the effective balance of environmental, social, and governance factors, HealthGen has not only been rated as an industry leader by S&P for two consecutive years but has also received widespread recognition from major authoritative institutions:
-
MSCI ESG rating upgraded to AA level;
-
China Securities Index ESG rating upgraded to AA level;
-
Awarded the "Guoxin Cup ESG Golden Bull Award Top 100";
-
First included in S&P Global's "Sustainability Yearbook (China Edition) 2024" 。
HealthGen, which has repeatedly appeared on the ESG lists of major authoritative institutions, is one of the representative ESG innovative pharmaceutical companies in China. The company deeply practices the concept of sustainable development, effectively integrating environmental, social, and governance factors to create an ESG system unique to "HealthGen".

Long-Term Value: ESG Promotes Enterprise Development
Currently, environmental, social, and governance factors, as the three major ESG indicators, are already familiar to the public. However, how to achieve a good and effective balance among the three is a major challenge for many companies in creating new ESG 'business cards'. HealthGen's ESG system undoubtedly provides a good reference for other companies.
E: Environmental Management Practice
The company adheres to the concept of green production, incorporating factors such as quality, safety, health, and environmental protection into its considerations to minimize the negative impact of all aspects of the product lifecycle on the environment and society. The company currently owns 18 advanced factories, including EU-certified production lines, 6 national-level green factories, and multiple unmanned workshops, promoting the continuous improvement of the green production system.
S: Social Responsibility Practice
The company has always been concerned about the medication issues of grassroots people. Based on its pharmaceutical company advantages, since 2018, it has joined hands with its holding subsidiary, Lizhu Group, to launch the "Affordable Chronic Disease Public Welfare Project" and has continued to implement it for 7 years. By the end of June 2024, this project has covered 9 provinces and 4 autonomous regions nationwide, benefiting more than 20,000 low-income people, effectively solving the problem of medication access in remote areas and alleviating the economic pressure on low-income families caused by long-term medication.
G: Focus on Corporate Governance
HealthGen deeply integrates the ESG development concept into its business operations, steadily improving the resilience of its business operations and ESG system construction. The company has always adhered to the principle of upholding the right path and pursuing innovation, closely following unmet clinical needs, and continuously expanding and enriching its new drug R&D pipeline with a forward-looking vision, achieving sustainable and high-quality development.

Focusing on Innovation: Promoting the Listing of Innovative Drugs to Benefit Patients Through Actual R&D and Fulfilling Long-Term ESG Commitments
Currently, HealthGen has a reserve of more than 20 innovative drugs, and 7 new drugs have successfully advanced to Phase II and beyond covering multiple therapeutic areas such as respiratory, analgesia, digestive system, cardiovascular, and mental diseases, and has formed a comprehensive and diversified product line.
Taking 2024 as an example, HealthGen implemented its innovative drug R&D strategy, with frequent good news in new drug R&D throughout the year. In terms of pipeline expansion, the company launched three innovative drug projects targeting chronic obstructive pulmonary disease (COPD) in the first quarter; and launched a new generation of glucocorticoid drugs, inhaled PDE4 inhibitors, and new β-lactamase inhibitor injections in September-December.
At the same time, the company's multiple new drugs under development are progressing smoothly, including the application for production of the anti-influenza drug mavapasinavir, which is expected to be launched this year; TSLP monoclonal antibody, GSNOR inhibitor, and MABA dual-target projects have all entered Phase II clinical trials. From the effective expansion of R&D projects to the orderly advancement of R&D projects, it marks that HealthGen's innovative drug R&D strategy is entering a stage of high-quality and rapid development.
Looking to the future, HealthGen will continue to pursue higher ESG standards, deepen the "HealthGen" ESG system, adhere to the importance of environmental, social, and governance factors, and set a good example of ESG governance for Chinese enterprises.